Have your own idea? Try our Stock Screener
Canadian (TSX) Biotech Industry Analysis
UpdatedApr 02, 2026
DataAggregated Company Financials
Companies25
- 7D-0.3%
- 3M-10.6%
- 1Y14.2%
- YTDn/a
Last week, the Biotech industry hasn't moved much but Eupraxia Pharmaceuticals is up 5.3% in that time. The past year has been better, since the industry has gained 14% in that time. Looking forward, earnings are forecast to decline by 4.6% per year.
Industry Valuation and Performance
Has the Canadian Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 02 Apr 2026 | CA$2.5b | CA$90.5m | -CA$254,182,995.83 | 50.9x | -9.9x | 27.8x |
| Sat, 28 Feb 2026 | CA$3.0b | CA$92.4m | -CA$239,113,248.00 | 53.7x | -12.3x | 31.9x |
| Mon, 26 Jan 2026 | CA$2.8b | CA$95.6m | -CA$242,084,260.72 | 22.4x | -11.6x | 29.5x |
| Wed, 24 Dec 2025 | CA$2.4b | CA$95.2m | -CA$237,667,790.65 | 22.9x | -10.2x | 25.4x |
| Fri, 21 Nov 2025 | CA$2.2b | CA$93.6m | -CA$230,542,047.24 | 23.4x | -9.7x | 23.8x |
| Sun, 19 Oct 2025 | CA$2.3b | CA$95.7m | -CA$236,129,606.49 | 23.9x | -9.6x | 23.7x |
| Tue, 16 Sep 2025 | CA$1.7b | CA$95.5m | -CA$223,213,832.44 | 25.8x | -7.5x | 17.6x |
| Thu, 14 Aug 2025 | CA$1.6b | CA$91.2m | -CA$215,129,154.01 | 21.4x | -7.5x | 17.6x |
| Sat, 12 Jul 2025 | CA$1.6b | CA$91.0m | -CA$270,901,181.84 | 22.7x | -6x | 17.7x |
| Mon, 09 Jun 2025 | CA$1.5b | CA$90.6m | -CA$303,927,469.18 | 22.5x | -4.9x | 16.4x |
| Wed, 07 May 2025 | CA$1.5b | CA$92.8m | -CA$284,267,363.87 | 21.4x | -5.1x | 15.7x |
| Fri, 04 Apr 2025 | CA$1.4b | CA$85.6m | -CA$297,998,945.46 | 22.8x | -4.7x | 16.4x |
| Sun, 02 Mar 2025 | CA$1.6b | CA$88.7m | -CA$317,724,572.99 | 23.8x | -4.9x | 17.6x |
| Tue, 28 Jan 2025 | CA$1.5b | CA$87.5m | -CA$318,045,297.30 | 24.4x | -4.8x | 17.3x |
| Thu, 26 Dec 2024 | CA$1.4b | CA$85.5m | -CA$321,484,405.12 | 15.2x | -4.5x | 16.9x |
| Sat, 23 Nov 2024 | CA$1.3b | CA$83.2m | -CA$247,884,407.28 | 8x | -5.3x | 15.9x |
| Mon, 21 Oct 2024 | CA$1.6b | CA$80.4m | -CA$280,068,283.41 | 9x | -5.7x | 20x |
| Wed, 18 Sep 2024 | CA$975.6m | CA$80.3m | -CA$274,259,968.97 | 9.1x | -3.6x | 12.2x |
| Fri, 16 Aug 2024 | CA$949.1m | CA$78.2m | -CA$288,533,287.85 | 9.1x | -3.3x | 12.1x |
| Sun, 14 Jul 2024 | CA$1.1b | CA$76.1m | -CA$335,920,138.88 | 10.4x | -3.4x | 15x |
| Tue, 11 Jun 2024 | CA$1.2b | CA$76.9m | -CA$342,724,091.67 | 11.5x | -3.4x | 15.1x |
| Thu, 09 May 2024 | CA$960.6m | CA$78.8m | -CA$301,831,223.10 | 322.2x | -3.2x | 12.2x |
| Sat, 06 Apr 2024 | CA$975.5m | CA$88.1m | -CA$279,564,051.80 | 10.2x | -3.5x | 11.1x |
| Mon, 04 Mar 2024 | CA$1.2b | CA$91.6m | -CA$325,002,294.97 | 11.5x | -3.6x | 12.7x |
| Wed, 31 Jan 2024 | CA$3.6b | CA$87.7m | -CA$517,016,070.00 | 6.9x | -6.9x | 40.7x |
| Fri, 29 Dec 2023 | CA$3.6b | CA$86.1m | -CA$521,531,504.00 | 7.2x | -6.9x | 41.9x |
| Sun, 26 Nov 2023 | CA$3.9b | CA$86.4m | -CA$546,993,598.00 | 5.9x | -7.1x | 45.1x |
| Tue, 24 Oct 2023 | CA$3.8b | CA$89.0m | -CA$532,523,252.00 | 5.4x | -7x | 42.1x |
| Thu, 21 Sep 2023 | CA$3.9b | CA$88.8m | -CA$517,147,287.00 | 5.7x | -7.5x | 43.9x |
| Sat, 19 Aug 2023 | CA$4.0b | CA$87.3m | -CA$524,804,745.00 | 6.7x | -7.6x | 45.4x |
| Mon, 17 Jul 2023 | CA$4.1b | CA$81.5m | -CA$516,636,148.00 | 14.2x | -7.9x | 49.9x |
| Wed, 14 Jun 2023 | CA$3.9b | CA$86.5m | -CA$547,763,851.00 | 12.4x | -7.2x | 45.5x |
| Fri, 12 May 2023 | CA$3.8b | CA$82.3m | -CA$586,384,543.00 | 12.2x | -6.5x | 46.1x |
| Sun, 09 Apr 2023 | CA$2.3b | CA$83.8m | -CA$596,271,188.00 | 11.1x | -3.9x | 27.8x |
Price to Earnings Ratio
-3.9x
Current Industry PE
- Investors are optimistic on the Canadian Biotechnology industry, and appear confident in long term growth rates.
- The 3-year average PS ratio of 25.3x is lower than the industry's current PS ratio of 27.8x.
Past Earnings Growth
- The earnings for companies in the Biotechnology industry have improved over the last three years.
- Revenues for these companies have grown 2.6% per year.
- This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.
Industry Comparison
How does Canadian Biotech compare with similar industries?
| CA Market | 1.56% | |
| Healthcare | 1.61% | |
| Biotech | -0.33% | |
| Biotech | -0.33% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| EPRX Eupraxia Pharmaceuticals | CA$10.31 | 5.3% +CA$32.0m | 129.1% | PB8.7x | |
| HBP Helix BioPharma | CA$1.80 | 5.3% +CA$6.9m | 129.3% | PB8.9x | |
| NRX NurExone Biologic | CA$0.65 | 10.2% +CA$5.5m | -3.0% | PB29.6x | |
| MOSS Moss Genomics | CA$0.075 | 150.0% +CA$2.9m | -61.5% | n/a | |
| MDNA Medicenna Therapeutics | CA$0.65 | 4.8% +CA$2.5m | -34.3% | PB8.7x |